Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184732 | 0.85 | GPBAR1 (0.61) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4182164 | 0.85 | GPBAR1 (0.61) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4184730 | 0.85 | GPBAR1 (0.61) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4186414 | 0.80 | GPBAR1 (0.52) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4169679 | 0.79 | ALDH1A1 (0.57) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4174339 | 0.79 | GPBAR1 (0.51) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4177315 | 0.78 | GPBAR1 (0.53) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4176872 | 0.78 | GPBAR1 (0.53) | L3MBTL1POLBGPBAR1CYP3A4CYP2C19 | |
| SCHEMBL4187068 | 0.74 | GLRA3 (0.63) | L3MBTL1GPBAR1 | |
| SCHEMBL4180216 | 0.74 | PKM (0.58) | GPBAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | L3MBTL1 4391/4885MAPK14 2339/4885POLB 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.